Expo Hub
WFNMB 2026
Discover our news in Nuclear Medicine.
We are looking forward to seeing you at WFNMB 2026 in
Cartagena, Colombia!
Welcome to the Siemens Healthineers experience at the 14th Congress of the World Federation of Nuclear Medicine and Biology, in Colombia.
Since creating the first gamma camera for SPECT imaging in 1958, we've remained committed to one mission: advancing molecular imaging to transform patient care worldwide.
Today, we invite you to explore how decades of innovation translate into breakthrough technologies that are redefining diagnostics and theranostics across the world. From our expanded Biograph Trinion PET/CT platform to the advances in Symbia Pro.specta theranostics edition — our comprehensive portfolio addresses every step of the molecular imaging patient pathway.
Discover how AI-powered syngo.via reading solutions are accelerating diagnoses, learn how our unified Radiopharma business is expanding access to critical radiopharmaceuticals, and experience firsthand why healthcare providers across the world trust Siemens Healthineers to deliver precision, reliability, and innovation.
The future of molecular imaging is here. Join us in shaping it together.
Congress information
Date: February, 13 - 16, 2026
Location: Cartagena, Colombia
Venue: Centro de Convenciones Cartagena de Indias
(maps)
Product highlights
Learn more about our product highlights from WFNMB 2026.
Don't miss our on-demand videos
1 / 0
PET amyloid imaging in clinical trials
Dr. Jacob Dubroff reviews the current state of new treatments for Alzheimer’s, with an emphasis on how advanced imaging techniques are critical to both diagnosing the disease early and monitoring treatment responses.
Amyloid PET in the diagnosis and management of patients with suspected Alzheimer disease
Dr. Jana Ivanidze discusses the latest developments in PET tracers and PET imaging, highlighting their role in early diagnosis.
Empowering precision oncology
Expanding access to next-generation theranostics
A powerful bond for cancer treatment: Incorporating molecular imaging with nuclear therapeutics
Dr. Ryan Avery shares his expertise and best practices about utilizing PET/CT as a diagnostic tool to appropriately select patients for theranostics treatments.
The exploration of ultra-low dose PET/CT and its implications for patient care
Dr. Eliot Siegel, MD explores the clinical utility of ultra-low dose PET/CT and its implications for patient care.
See our complete portfolio
Nuclear Medicine News & Stories
Your resource for the latest news, stories, and clinical cases in nuclear medicine and molecular imaging.
Biograph Vision Quadra News & Stories
In this special edition of Nuclear Medicine News & Stories, deepen the dimension of your investigations, explore new research questions, and identify the best clinical approach for your patients with Biograph Vision Quadra.
Thank you for joining us at WFNMB 2026.
1BIOGRAPH One is currently under development and not commercially available. It’s not for sale in the U.S.A. Its future availability cannot be ensured.
Biograph Trinion, Biograph Vision Quadra, and Symbia Pro.specta are not commercially available in all countries. Future availability cannot be guaranteed.